Think Trial: Phase I Results For Nkg2d Car-t Therapy In Aml

2019 4:03
Synopsis
CYAD-01 is a CAR T-cell product based on the Natural Killer Group 2D (NKG2D) receptor. Here, David Sallman, MD, of the Moffitt ...

You Might Also Like

David Sallman | ASH 2018 | Key results of the phase I THINK trial of NKG2D CAR-T therapy in R/R AML 3:33
David Sallman | Ash 2018 | Key Results Of The Phase I Think ...
2019
NKG2D-based CAR-T in R/R AML and MDS 2:21
Nkg2d-based Car-t In R/r Aml And Mds
2020
Insights into NKG2D-targeting CAR-T cells in R/R AML 1:30
Insights Into Nkg2d-targeting Car-t Cells In R/r Aml
2024
NKG2D CAR-T cell therapy in AML/MDS 2:00
Nkg2d Car-t Cell Therapy In Aml/mds
2022
Dr. Park on Challenges With CAR T cells in AML 0:39
Dr. Park On Challenges With Car T Cells In Aml
2020
The future for CAR T-cells in treating AML 0:44
The Future For Car T-cells In Treating Aml
2018
David Sallman, MD, offers details regarding the clinical investigation of CYAD-01 2:07
David Sallman, Md, Offers Details Regarding The Clinical Inv...
2021
NKG2D CARs for R/R AML and MDS 1:47
Nkg2d Cars For R/r Aml And Mds
2020
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS 2:29
Cycle-1: Next Generation Nkg2d-based Car T-cells In Aml/mds
2022
Examining the Current Role of CAR T-Cell Therapy in Acute Myeloid Leukemia 1:34
Examining The Current Role Of Car T-cell Therapy In Acute My...
2020
Design of a Phase I trial of allogeneic anti-CD123 CAR T-cells in R/R AML 2:20
Design Of A Phase I Trial Of Allogeneic Anti-cd123 Car T-cel...
2021
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.